Now medical providers can bill for the use of TheraSkin more efficiently and recieve faster payment from the Rhode Island Dept. of Human Services (Medicaid).

NEWPORT NEWS, Virginia (August 28, 2013) – The Rhode Island Department of Human Services has notified Soluble Systems, LLC, that TheraSkin pricing has been added to the RI Medicaid fee schedule. Healthcare providers can now benefit from a more efficient claims filing process, faster action on payment requests and improved cash flow. The current fee schedule (August, 2013) can be found at: 

“We were pleased when Rhode Island originally decided to cover this limb and life-saving product, and are very pleased that the reimbursement process has now been simplified by automatic pricing on the fee schedule” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that Rhode Island Medicaid patients with diabetic and venous leg ulcers will now have easier access to cost-effective living cell therapy. Patients who have particularly benefited from the wound healing capabilities of TheraSkin are those with diabetes.

“Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.

TheraSkin is not only clinically effective, but economical, costing 50 – 70% less than competing biologically active products, saving patients and payers thousands of dollars per treatment. A potent new weapon in the battle against rising healthcare costs, TheraSkin has the potential to save patients and the U.S. healthcare system more than $1 billion over the next decade.

TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing. Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing.

Comments are closed.